Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
Serum and cerebrospinal fluid (CSF) levels of haloperidol were measured in 12 chronic neuroleptic-nonresponsive schizophrenic patients after 1 month on 60 mg haloperidol daily and then again after 1 month on 120 mg haloperidol daily. Serum haloperidol and CSF haloperidol rose with increasing dose. Serum and CSF levels were significantly correlated. No clinical improvement was achieved despite the high serum and CSF drug levels.
D004351:Drug Resistance; D006220:Haloperidol / Q000097:blood / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D006801:Humans; D011863:Radioimmunoassay; D011869:Radioligand Assay; D012559:Schizophrenia / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy*
D006220:Haloperidol